Ultragenyx Pharmaceutical Inc.

Nasdaq:RARE

Pharmaceutical Preparations·NOVATO, CA

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need.

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	2/18/26	→
10-Q	Q3 2025	9/30/25	11/5/25	→
10-Q	Q2 2025	6/30/25	8/6/25	→
10-Q	Q1 2025	3/31/25	5/7/25	→
10-K	FY 2024	12/31/24	2/19/25	→
10-Q	Q3 2024	9/30/24	11/6/24	→
↓

Earnings Releases (8-K)

27 shown

Filed	Period
2/12/26	Q1 FY2026	→
1/12/26	Q4 FY2026	→
11/4/25	Q4 FY2025	→
8/5/25	Q3 FY2025	→
5/6/25	Q2 FY2025	→
2/13/25	Q1 FY2025	→
↓

News (8-K)

53 shown

Filed	Type	Description
2/23/26	Other	Other Events	→
2/3/26	Other	Other Events	→
1/30/26	Other	Other Events	→
12/30/25	Other	Other Events	→
12/29/25	Other	Other Events	→
10/30/25	Other	Other Events	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
7/18/25	S-8	S-8	→
3/28/25	ARS	ANNUAL REPORT TO SECURITY HOLDERS	→
7/12/24	S-8	S-8	→
6/14/24	424B5	424B5	→
6/12/24	424B5	424B5	→
4/26/24	ARS	ULTRAGENYX PHARMACEUTICAL INC. - ARS	→
↓

Filing History(1001 filings)

TypeDateAccessionPeriodSize

144

Mar 6, 2026

0001950047-26-002334

—

5.7 KB

Mar 3, 2026

0001193125-26-0892874

Mar 1, 2026

7.0 KB

Mar 3, 2026

0001193125-26-0892824

Mar 1, 2026

6.9 KB

Mar 3, 2026

0001193125-26-0892784

Mar 1, 2026

7.6 KB

Mar 3, 2026

0001193125-26-0891114

Mar 1, 2026

6.9 KB

Mar 3, 2026

0001193125-26-0891094

Mar 2, 2026

6.7 KB

Mar 3, 2026

0001193125-26-0891074

Mar 1, 2026

9.4 KB

Mar 3, 2026

0001193125-26-0891044

Mar 1, 2026

6.9 KB

Mar 3, 2026

0001193125-26-0891024

Mar 1, 2026

6.3 KB

144

Mar 3, 2026

0001950047-26-002108

—

8.5 KB

144

Mar 2, 2026

0001950047-26-002038

—

7.2 KB

8-K

Feb 23, 2026

0001193125-26-0625688-K

Feb 23, 2026

149.7 KB

10-K

Feb 18, 2026

0001193125-26-05732910-K

Dec 31, 2025

19.0 MB

8-K

Feb 12, 2026

0001193125-26-0487388-K

Feb 12, 2026

553.2 KB

SCHEDULE 13G/A

Feb 5, 2026

0000315066-26-000545

—

11.1 KB

Feb 3, 2026

0001193125-26-0348324

Feb 2, 2026

4.5 KB

8-K

Feb 3, 2026

0001193125-26-0344748-K

Feb 3, 2026

170.0 KB

144

Feb 2, 2026

0001950047-26-000800

—

6.5 KB

8-K

Jan 30, 2026

0001193125-26-0305908-K

Jan 30, 2026

151.6 KB

8-K

Jan 12, 2026

0001193125-26-0097918-K

Jan 12, 2026

222.0 KB

Jan 5, 2026

0001193125-26-0024104

Jan 2, 2026

4.5 KB

144

Jan 2, 2026

0001950047-26-000020

—

6.5 KB

8-K

Dec 30, 2025

0001193125-25-3370998-K

Dec 30, 2025

149.7 KB

Dec 30, 2025

0001193125-25-3366194

Dec 29, 2025

4.9 KB

8-K

Dec 29, 2025

0001193125-25-3324228-K

Dec 29, 2025

154.3 KB

25 filings shown

Ultragenyx Pharmaceutical Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(1001 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/28/25	DEFA14A	DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS	→
3/28/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
4/26/24	DEFA14A	ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A	→
4/26/24	DEF 14A	ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A	→
4/24/23	DEFA14A	ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A	→
4/24/23	DEF 14A	ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A	→
↓

Filed	Form	Description
3/3/26	4	4	→
3/3/26	4	4	→
3/3/26	4	4	→
3/3/26	4	4	→
3/3/26	4	4	→
3/3/26	4	4	→
↓

Filed	Form	Description
3/6/26	144	144	→
3/3/26	144	144	→
3/2/26	144	144	→
2/5/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/2/26	144	144	→
1/2/26	144	144	→
↓